Cohbar Inc Stock Price, News & Analysis

CohBar, Inc. (NASDAQ: CWBR), a biotechnology firm focused on mitochondria-based therapeutics, announced that CEO Steven Engle will present a company update at the BIO Investor Forum from October 13-15, 2020. The event is held virtually, and the presentation will be available on demand. CohBar is in Phase 1b of a clinical trial for its lead compound, CB4211, addressing NASH and obesity. The company has also developed several preclinical programs targeting various diseases linked to mitochondrial dysfunction.

CohBar, a clinical stage biotechnology company, announced today that CEO Steven Engle will present an update at the H.C. Wainwright 4th Annual NASH Investor Conference. This virtual event is scheduled for October 5, 2020, at 12:00 PM ET. CohBar focuses on developing mitochondria-based therapeutics, with its lead compound CB4211 currently in a Phase 1b clinical trial targeting NASH and obesity. Furthermore, the company has four preclinical programs aimed at various chronic and age-related diseases, showcasing its commitment to addressing mitochondrial dysfunction.

CohBar, a clinical stage biotechnology company (NASDAQ: CWBR), will present an update at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, at 12:00 PM ET. CEO Steven Engle will discuss the company's focus on developing mitochondria-based therapeutics aimed at treating chronic diseases and enhancing healthy lifespan. CohBar's lead compound, CB4211, is in Phase 1b clinical trials for NASH and obesity, along with additional preclinical programs targeting various diseases. More information can be accessed via a webcast.

CohBar, a clinical stage biotechnology company focused on mitochondria-based therapeutics, announced that CEO Steven Engle will present an update at the Oppenheimer Fall Healthcare Summit on September 22, 2020, at 2:30 PM ET. The presentation will explore the company's advancements in developing therapies aimed at treating chronic diseases and extending healthy lifespans. CohBar's lead compound, CB4211, is in Phase 1b trials for NASH and obesity, with four additional preclinical programs targeting various diseases. For more details, access the presentation via webcast.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company, announced that CEO Steven Engle will present a company update at the H.C. Wainwright Annual Global Investment Conference, held virtually from September 14-16, 2020. Engle's presentation is scheduled for September 15 at 4:00 PM ET, which can be accessed via webcast. CohBar focuses on mitochondria-based therapeutics for chronic diseases, with its lead compound CB4211 in Phase 1b clinical trials for NASH and obesity, alongside four preclinical programs targeting various diseases.

CohBar, Inc. (NASDAQ: CWBR) has successfully closed its public offering of 12,300,000 units at $1.22 each, raising approximately $15.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.75 shares at $1.44, with the underwriters partially exercising an over-allotment option for additional warrants. The offering is part of a shelf registration filed with the SEC. Funds from this offering are intended to support the development of CohBar’s mitochondria-based therapeutics, including its lead compound, CB4211, currently in a Phase 1b trial for NASH and obesity.

CohBar, Inc. (NASDAQ: CWBR) announced a proposed underwritten public offering of units, which includes one share of common stock and a warrant to purchase 0.75 shares. Each warrant is exercisable for five years post-offering closure. The company plans to use net proceeds for general corporate purposes, including funding preclinical and clinical developments and increasing working capital. Roth Capital Partners is the sole book-running manager, with additional co-managers. The offering is subject to market conditions and no assurance can be given regarding its completion.

CohBar, Inc. (NASDAQ: CWBR) announced the dosing of the first subjects in the Phase 1b clinical trial for CB4211, targeting NASH and obesity. Conducted on twenty obese participants with NAFLD, the study aims to evaluate the drug's effects on liver fat and body weight over four weeks. This is the first mitochondria-based therapeutic to enter clinical testing, with preclinical studies showing promise in regulating metabolism. CohBar anticipates topline data in Q1 2021, addressing a significant market need, with over 30 million patients affected by NASH in the U.S.

CohBar, Inc. (CWBR) has reported preliminary positive results from its COVID-19 ARDS program, marking a significant advancement in its clinical research efforts. The company resumed its Phase 1b clinical study for treating NASH and obesity and raised $4.5 million from an at-the-market offering. Financial highlights for Q2 2020 include a net loss of $4.1 million and cash reserves of $12.3 million. CohBar also joined the Russell 2000 and 3000 Indexes, enhancing its market visibility. A conference call to discuss the results is scheduled for 5:00 p.m. ET on August 13, 2020.